Opportunity Information: Apply for PAR 13 025
Apply for PAR 13 025
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Selected Topics in Transfusion Medicine (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Nov 23, 2012 and posted on Nov 23, 2012.
- Applicants must submit their applications by Jan 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: City or township governments Private institutions of higher education Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Others (see text field entitled Additional Information on Eligibility for clarification) County governments Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments For profit organizations other than small businesses Special district governments Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Selected Topics in Transfusion Medicine (R21) grant opportunity (Funding Opportunity Number PAR-13-025) was a National Institutes of Health (NIH) program run through the National Heart, Lung, and Blood Institute (NHLBI) to support exploratory and developmental research in blood banking and transfusion medicine. The central purpose of the announcement was to encourage studies that could strengthen both the safety and the availability of the blood supply while also improving day-to-day transfusion practice. In practical terms, the FOA targeted projects that could generate new insights, early-stage data, or proof-of-concept findings that would ultimately help protect donors and recipients, reduce preventable harms, and ensure the healthcare system has reliable access to needed blood products.
A major emphasis of the FOA was improving blood donor health and minimizing risks tied to the donation process. That includes research aimed at understanding donor reactions and complications, identifying factors that make donation safer for different donor groups, and developing strategies to prevent adverse donor outcomes. Alongside donor safety, the announcement highlighted the need to improve recruitment and retention, recognizing that maintaining an adequate and stable blood supply depends not only on medical safety but also on effective donor engagement, repeat donation, and reducing barriers that keep eligible people from donating.
The FOA also focused heavily on the safety, quality, and availability of blood products themselves. Projects could address ways to reduce infectious and non-infectious risks, improve how blood products are collected, processed, stored, and distributed, or develop approaches that increase the usable supply without compromising safety. Another stated priority was improving the practice of transfusion medicine, including research that clarifies when transfusions are most beneficial, how to optimize transfusion decisions, and how clinical protocols might be refined to improve outcomes for patients who receive blood components.
A specific area called out in the description was transfusion-associated adverse events. The FOA encouraged research designed to better understand what causes these adverse events, what patient, product, or procedural factors predict them, and what interventions are most effective at reducing risk. The idea was to move beyond simply documenting that adverse events occur and instead identify determinants, mechanisms, and prevention strategies that could be translated into safer clinical practice.
Mechanistically, this opportunity used the NIH R21 funding mechanism, which is generally intended for early-stage, high-impact, or innovative projects that may still be developing their evidence base. The listed award ceiling was $200,000, and the program did not require cost sharing or matching. The funding activity category was health, and it was associated with CFDA 93.839 (Blood Diseases and Resources Research). The opportunity was posted on November 23, 2012, and the final closing date was January 7, 2017, with an archive date of February 7, 2017, meaning it is no longer open but remains relevant as a reference point for the kinds of transfusion medicine research priorities NHLBI has supported.
Eligibility was broad and included many U.S. organization types such as state and local governments, public and private institutions of higher education, nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) nonprofits), small businesses, and for-profit organizations other than small businesses. The FOA also allowed participation from tribal governments and tribal organizations, public housing authorities, independent school districts, and special district governments. Importantly, it also permitted non-U.S. entities and foreign institutions to apply, allowed non-U.S. components of U.S. organizations, and allowed foreign components as defined by NIH policy. The eligibility language also explicitly included various minority-serving and specialized institutions (for example, HBCUs, Hispanic-serving institutions, AANAPISIs, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions), as well as faith-based and community-based organizations and U.S. territories or possessions.
Overall, PAR-13-025 was structured to push forward practical, public-health-relevant research on transfusion medicine: protecting donors, improving product safety and availability, reducing transfusion complications, and strengthening recruitment and retention so the blood system can meet clinical needs reliably. The full announcement was made available through the NIH grants guide at http://grants.nih.gov/grants/guide/pa-files/PAR-13-025.html, and NIH provided support contact information through the Office of Extramural Research (OER) webmaster for access or linking issues.
FAQs: Selected Topics in Transfusion Medicine (R21) (PAR-13-025)
What is the Selected Topics in Transfusion Medicine (R21) opportunity?
Selected Topics in Transfusion Medicine (R21) (Funding Opportunity Number PAR-13-025) was a National Institutes of Health (NIH) funding opportunity run through the National Heart, Lung, and Blood Institute (NHLBI). It supported exploratory and developmental research in blood banking and transfusion medicine.
What was the main goal of this FOA?
The central goal was to encourage studies that strengthen both the safety and the availability of the blood supply and improve day-to-day transfusion practice. The FOA aimed to generate new insights, early-stage data, or proof-of-concept findings that could help protect donors and recipients, reduce preventable harms, and support reliable access to needed blood products.
What NIH funding mechanism was used?
This opportunity used the NIH R21 mechanism, which is generally intended for early-stage, high-impact, or innovative projects that may still be developing their evidence base.
How much funding was available per award?
The listed award ceiling was $200,000.
Was cost sharing or matching required?
No. The program did not require cost sharing or matching.
Which NIH institute administered this program?
The program was administered through NIH's National Heart, Lung, and Blood Institute (NHLBI).
What research areas did the FOA emphasize?
The FOA emphasized research that could improve blood donor health and safety, strengthen recruitment and retention, enhance the safety, quality, and availability of blood products, and improve transfusion medicine practice, including reducing transfusion-associated adverse events.
What kinds of donor safety topics were encouraged?
The FOA encouraged research to better understand donor reactions and complications, identify factors that make donation safer for different donor groups, and develop strategies to prevent adverse donor outcomes.
Did the FOA address donor recruitment and retention?
Yes. It highlighted improving recruitment and retention, recognizing that a stable blood supply depends on effective donor engagement, repeat donation, and reducing barriers that keep eligible people from donating.
What types of blood product research were in scope?
Projects could address reducing infectious and non-infectious risks, improving how blood products are collected, processed, stored, and distributed, and developing approaches that increase the usable supply without compromising safety.
Did the FOA include research on transfusion practice and clinical decision-making?
Yes. It supported research that clarifies when transfusions are most beneficial, how to optimize transfusion decisions, and how clinical protocols might be refined to improve outcomes for patients receiving blood components.
What did the FOA say about transfusion-associated adverse events?
Transfusion-associated adverse events were specifically called out. The FOA encouraged studies to understand causes and mechanisms, identify patient/product/procedural predictors, and test interventions aimed at reducing risk and translating findings into safer clinical practice.
What was the funding activity category and CFDA number?
The funding activity category was health, and it was associated with CFDA 93.839 (Blood Diseases and Resources Research).
When was this opportunity posted?
The FOA was posted on November 23, 2012.
When did the opportunity close?
The final closing date was January 7, 2017.
Is this FOA still open?
No. It is no longer open. The archive date was February 7, 2017.
Why might PAR-13-025 still matter if it is closed?
Even though it is archived, it remains a useful reference for the kinds of transfusion medicine research priorities NHLBI has supported, such as donor protection, product safety and availability, reduction of transfusion complications, and strengthening recruitment and retention.
Who was eligible to apply?
Eligibility was broad and included many U.S. organization types, including state and local governments, public and private institutions of higher education, nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) nonprofits), small businesses, and for-profit organizations other than small businesses.
Were tribal and local public entities eligible?
Yes. The FOA allowed participation from tribal governments and tribal organizations, as well as public housing authorities, independent school districts, and special district governments.
Were non-U.S. or foreign organizations eligible?
Yes. The FOA permitted non-U.S. entities and foreign institutions to apply. It also allowed non-U.S. components of U.S. organizations and foreign components as defined by NIH policy.
Did the FOA explicitly include minority-serving and specialized institutions?
Yes. The eligibility language explicitly included minority-serving and specialized institutions such as HBCUs, Hispanic-serving institutions, AANAPISIs, tribally controlled colleges and universities, and Alaska Native and Native Hawaiian serving institutions.
Were faith-based and community-based organizations eligible?
Yes. Faith-based and community-based organizations were explicitly included in the eligibility language.
Were U.S. territories or possessions included?
Yes. U.S. territories or possessions were included.
Where could applicants find the full announcement?
The full announcement was available through the NIH grants guide at http://grants.nih.gov/grants/guide/pa-files/PAR-13-025.html.
Who was listed as a contact for access or linking issues?
NIH provided support contact information through the Office of Extramural Research (OER) webmaster for access or linking issues.
Browse more opportunities from the same category: Health
Next opportunity: Selected Topics in Transfusion Medicine (R01)
Previous opportunity: Morris K. Udall Centers of Excellence for Parkinsons Disease Research (P50)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 025
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 025) also looked into and applied for these:
| Funding Opportunity |
|---|
| Selected Topics in Transfusion Medicine (R01) Apply for PAR 13 026 Funding Number: PAR 13 026 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Health Workforce Research Center (HWRC) Program Apply for HRSA 13 185 Funding Number: HRSA 13 185 Agency: Health Resources and Services Administration Category: Health Funding Amount: $500,000 |
| Nurse Education, Practice, Quality and Retention (NEPQR) Program Interprofessional Collaborative Practice Apply for HRSA 13 188 Funding Number: HRSA 13 188 Agency: Health Resources and Services Administration Category: Health Funding Amount: $500,000 |
| HIV Early Intervention Services (EIS) Program Existing Geographic Service Areas (EISEGA) Apply for HRSA 13 168 Funding Number: HRSA 13 168 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Community Based Dental Partnership Program Apply for HRSA 13 170 Funding Number: HRSA 13 170 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Natural History and Prevention of Viral Hepatitis Among Alaska Natives Apply for RFA PS 13 001 Funding Number: RFA PS 13 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Advanced Nursing Education Program Apply for HRSA 13 186 Funding Number: HRSA 13 186 Agency: Health Resources and Services Administration Category: Health Funding Amount: $375,000 |
| Communication for Healthy Communities Apply for RFA 617 13 000001 Funding Number: RFA 617 13 000001 Agency: Uganda USAID Kampala Category: Health Funding Amount: $50,000,000 |
| Medical Home Implementation for Children with Special Health Care Needs Apply for HRSA 13 216 Funding Number: HRSA 13 216 Agency: Health Resources and Services Administration Category: Health Funding Amount: $800,031 |
| National Center on Health Care Transition for Youth with Special Health Care Needs Apply for HRSA 13 218 Funding Number: HRSA 13 218 Agency: Health Resources and Services Administration Category: Health Funding Amount: $436,160 |
| Coordinating Center for an Undiagnosed Diseases Network (UDN) (U01) Apply for RFA RM 12 020 Funding Number: RFA RM 12 020 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Evaluation of Multi omic Data in Understanding the Human Microbiomes Role in Health and Disease (U54) Apply for RFA RM 12 021 Funding Number: RFA RM 12 021 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Technology Development for High Throughput Structural Biology Research (R01) Apply for PAR 13 032 Funding Number: PAR 13 032 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Nurse Faculty Loan Program (NFLP) Apply for HRSA 13 189 Funding Number: HRSA 13 189 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Technology Development for Protein Modeling (R01) Apply for PAR 13 033 Funding Number: PAR 13 033 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Small Health Care Provider Quality Improvement Grant Program Apply for HRSA 13 159 Funding Number: HRSA 13 159 Agency: Health Resources and Services Administration Category: Health Funding Amount: $150,000 |
| Birth Defects Study To Evaluate Pregnancy exposureS (BD STEPS) Apply for RFA DD 13 003 Funding Number: RFA DD 13 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| New Methods for Understanding the Functional Role of Human DNA Sequence Variants in Complex Phenotypes (R01) Apply for RFA GM 14 006 Funding Number: RFA GM 14 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Service Area Competition Additional Area (SAC AA) East Chicago, Indiana Apply for HRSA 13 263 Funding Number: HRSA 13 263 Agency: Health Resources and Services Administration Category: Health Funding Amount: $783,114 |
| NIMHD Transdisciplinary Collaborative Centers for Research on Mens Health (U54) Apply for RFA MD 13 004 Funding Number: RFA MD 13 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 025", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.